Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan:132:102863.
doi: 10.1016/j.ctrv.2024.102863. Epub 2024 Nov 26.

Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review

Natalia Soledad Tissera  1 , Francesca Balconi  2 , Alejandro García-Álvarez  3 , Jorge Hernando Cubero  3 , Juan Manuel O'Connor  4 , Matías Chacón  5 , Jaume Capdevila  3
Affiliations
Free article
Review

Maintenance therapy after first-line platinum-based chemotherapy in gastroenteropancreatic neuroendocrine carcinomas: A literature review

Natalia Soledad Tissera et al. Cancer Treat Rev. 2025 Jan.
Free article

Abstract

Neuroendocrine carcinomas are rare and aggressive malignancies, often diagnosed at advanced stages, leading to poor prognosis. Platinum-based chemotherapy is the standard first-line treatment for advanced neuroendocrine carcinomas; however after achieving response no consensus exists on maintenance therapies and the results are inconsistent. This review examines the role of maintenance therapy following response to first-line chemotherapy in gastroenteropancreatic neuroendocrine carcinomas. We identified limited supporting evidence, primarily from phase II trials and case reports, that suggested maintenance therapy could be considered for prolonging progression-free survival, balancing toxicity, and maintaining quality of life. Nevertheless, prospective studies are needed to validate its clinical efficacy.

Keywords: Advanced; First-line chemotherapy; Gastroenteropancreatic; Maintenance therapy; Neuroendocrine carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Natalia Soledad Tissera reports a grant from Fundació Catalunya La Pedrera—VHIO MD-PhD fellowship. Alejandro Garcia-Álvarez declares the following potential conflicts of interest: Speakers' Bureau: EISAI Europe, Lilly; Travel, Accommodations, Expenses: Advanz, EISAI, Ipsen, ADACAP (Novartis), Amgen, Pfizer, Lilly. Jaume Capdevila declares scientific consultancy role (speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Hudchmed, ITM, Merck Serono, Roche, Esteve, Advanz; research grants from Novartis, Pfizer, Astrazeneca, Advanced Accelerator Applications, Eisai, Amgen, ITM, Roche, Gilead and Bayer. All other authors have declared no conflicts of interest.

MeSH terms

Supplementary concepts

LinkOut - more resources